<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216226</url>
  </required_header>
  <id_info>
    <org_study_id>ZP4207-16136</org_study_id>
    <nct_id>NCT03216226</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen® Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynteractHCR</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial's objective is to evaluate the immunogenicity of repeated single doses of&#xD;
      dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1&#xD;
      diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon&#xD;
      and GlucaGen.&#xD;
&#xD;
      *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with T1DM were randomly assigned in a 1:1 ratio to receive 3 SC injections of either&#xD;
      dasiglucagon (0.6 mg) or GlucaGen (1 mg), with 1 week between doses. Patients were followed&#xD;
      for 15 weeks from the day of the first dose to assess the immune response. Patients with&#xD;
      previous exogenic glucagon exposure were not excluded from the trial, but the information on&#xD;
      previous glucagon administration was recorded to enable subgroup analyses. It was expected&#xD;
      that 112 patients in total would be randomly assigned to treatment groups and treated. A&#xD;
      total of 90 patients were expected to complete the trial (45 in each treatment arm). To&#xD;
      qualify as completed, the patient had to be dosed according to the procedure described in the&#xD;
      protocol and to have blood drawn for the antidrug antibody analyses as scheduled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">February 13, 2018</completion_date>
  <primary_completion_date type="Actual">February 13, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With ADA</measure>
    <time_frame>104 days after the first dose</time_frame>
    <description>Percentage of the combined results of treatment-induced ADA-positive patients and treatment-boosted ADA-positive patients out of the total number of evaluable patients. ADA = antidrug antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Treatment-induced ADA</measure>
    <time_frame>104 days after the first dose</time_frame>
    <description>Percentage of the total number of evaluable patients that were ADA negative at baseline and ADA positive after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Treatment-boosted ADA</measure>
    <time_frame>104 days after the first dose</time_frame>
    <description>Percentage of baseline ADA-positive patients with significant increases (≥5-fold) in ADA titre after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of ADA Response - Neutralizing Activity</measure>
    <time_frame>104 days after the first dose</time_frame>
    <description>Percentage of ADA positive patients with ADA neutralizing activity. ADA = antidrug antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of ADA Response - Titer of Neutralizing Activity</measure>
    <time_frame>104 days after the first dose</time_frame>
    <description>Titre of neutralizing activity of ADA positive patients. ADA = antidrug antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of ADA Response - Cross-reactivity</measure>
    <time_frame>104 days after the first dose</time_frame>
    <description>Percentage of ADA positive patients with cross-reactivity towards endogenous glucagon. ADA = antidrug antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of ADA Response - Timing</measure>
    <time_frame>104 days after the first dose</time_frame>
    <description>The timing of detected ADA response. ADA = antidrug antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of ADA Response - Duration</measure>
    <time_frame>104 days after the first dose</time_frame>
    <description>The Duration of detected ADA response. ADA = antidrug antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area Under the Plasma Concentration Curve</measure>
    <time_frame>0-30 minutes</time_frame>
    <description>Area under the plasma concentration curve (AUC) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area Under the Plasma Concentration Curve</measure>
    <time_frame>0-90 minutes</time_frame>
    <description>Area under the plasma concentration curve (AUC) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum Plasma Concentration</measure>
    <time_frame>90 minutes</time_frame>
    <description>Maximum plasma concentration (Cmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time to Maximum Plasma Concentration</measure>
    <time_frame>90 minutes</time_frame>
    <description>Time to maximum plasma concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Area Under the Effect Curve</measure>
    <time_frame>0-30 minutes</time_frame>
    <description>Plasma glucose profiles, area under the effect curve (AUE) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Area Under the Effect Curve</measure>
    <time_frame>0-90 minutes</time_frame>
    <description>Plasma glucose profiles, area under the effect curve (AUE) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Change From Baseline Plasma Glucose</measure>
    <time_frame>90 minutes</time_frame>
    <description>Change from baseline plasma glucose to maximum plasma glucose (CEmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Time to Maximum Plasma Glucose Concentration</measure>
    <time_frame>90 minutes</time_frame>
    <description>Time to maximum plasma glucose concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment</measure>
    <time_frame>30 minutes</time_frame>
    <description>An increase in the plasma glucose concentration of ≥20 mg/dL within 30 minutes after treatment at visit 2 and visit 4. Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>dasiglucagon (ZP4207)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated single fixed doses (s.c.injection) of dasiglucagon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GlucaGen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated single fixed doses (s.c.injection) of GlucaGen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasiglucagon</intervention_name>
    <description>Glucagon Analog</description>
    <arm_group_label>dasiglucagon (ZP4207)</arm_group_label>
    <other_name>ZP4207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GlucaGen</intervention_name>
    <description>Native Glucagon</description>
    <arm_group_label>GlucaGen</arm_group_label>
    <other_name>GlucaGen HypoKit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities (trial-related&#xD;
             activities are any procedure that would not have been performed during normal&#xD;
             management of the patient)&#xD;
&#xD;
          -  Availability for the entire trial period&#xD;
&#xD;
          -  Age between 18 and 70 years, both inclusive&#xD;
&#xD;
          -  Male or female patients with T1DM for at least 1 year. Diagnostic criteria as defined&#xD;
             by the American Diabetes Association&#xD;
&#xD;
          -  Hemoglobin A1c (HbA1c) &lt;10%&#xD;
&#xD;
          -  Stable anti-diabetic treatment for at least 1 month (e.g. within 10% insulin dose&#xD;
             adjustment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous administration of dasiglucagon (previously referred to as ZP4207)&#xD;
&#xD;
          -  Known or suspected allergy to trial medication(s) or related products&#xD;
&#xD;
          -  History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema)&#xD;
&#xD;
          -  Previous participation (randomization) in this trial&#xD;
&#xD;
          -  Females who are pregnant according to a positive pregnancy test, actively attempting&#xD;
             to get pregnant, or are lactating&#xD;
&#xD;
          -  Patients on a closed loop artificial pancreas&#xD;
&#xD;
          -  Receipt of any investigational drug within 3 months prior to screening&#xD;
&#xD;
          -  Active malignancy within the last 5 years&#xD;
&#xD;
          -  Congestive heart failure, New York Heart Association class II-IV&#xD;
&#xD;
          -  Inadequately treated blood pressure as defined as systolic blood pressure ≥160 mmHg or&#xD;
             diastolic blood pressure ≥90 mmHg at screening&#xD;
&#xD;
          -  Current bleeding disorder, including use of anticoagulant treatment&#xD;
&#xD;
          -  Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma&#xD;
             (i.e. insulin-secreting pancreas tumor)&#xD;
&#xD;
          -  Known or suspected HIV infection&#xD;
&#xD;
          -  Use of a systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs&#xD;
             in the previous 28 days before Day 1 of this trial&#xD;
&#xD;
          -  Use of systemic corticosteroids, anti-inflammatory biological agents, kinase&#xD;
             inhibitors or other immune modulating agents within the last 3 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks&#xD;
             prior to screening&#xD;
&#xD;
          -  A positive result in the alcohol and/or urine drug screen at the screening visit.&#xD;
             Significant history of alcoholism or drug abuse as judged by the investigator or&#xD;
             consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day&#xD;
             for women.&#xD;
&#xD;
          -  Surgery or trauma with significant blood loss within the last 2 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Use of prescription or non-prescription medications known to cause QT prolongation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Sylvest, MSc Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRC - Clinical Research Center, Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Manna Research</name>
      <address>
        <city>Barrie</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Calgary</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes &amp; Manna Research</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <results_first_submitted>January 27, 2021</results_first_submitted>
  <results_first_submitted_qc>January 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2021</results_first_posted>
  <disposition_first_submitted>March 27, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 2, 2019</disposition_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucagon</keyword>
  <keyword>Dasiglucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03216226/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03216226/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dasiglucagon (ZP4207)</title>
          <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
        </group>
        <group group_id="P2">
          <title>GlucaGen</title>
          <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient unable to take time off work to come in for the third injection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Deviation from protocol window during visit as patient had to leave for work</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrawn prior to treatment. Patient veins unsuitable for blood draws</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are presented for the patients who were randomized and treated: 111 in total</population>
      <group_list>
        <group group_id="B1">
          <title>Dasiglucagon (ZP4207)</title>
          <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
        </group>
        <group group_id="B2">
          <title>GlucaGen</title>
          <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="12.21"/>
                    <measurement group_id="B2" value="38.8" spread="13.65"/>
                    <measurement group_id="B3" value="42.1" spread="13.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.9" spread="18.44"/>
                    <measurement group_id="B2" value="82.7" spread="16.25"/>
                    <measurement group_id="B3" value="82.8" spread="17.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="4.88"/>
                    <measurement group_id="B2" value="27.4" spread="4.70"/>
                    <measurement group_id="B3" value="27.3" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With ADA</title>
        <description>Percentage of the combined results of treatment-induced ADA-positive patients and treatment-boosted ADA-positive patients out of the total number of evaluable patients. ADA = antidrug antibodies.</description>
        <time_frame>104 days after the first dose</time_frame>
        <population>Full analysis set of all patients in the safety analysis set (those randomized who received at least 1 dose of trial product) with at least 1 measurement of ADA titres at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With ADA</title>
          <description>Percentage of the combined results of treatment-induced ADA-positive patients and treatment-boosted ADA-positive patients out of the total number of evaluable patients. ADA = antidrug antibodies.</description>
          <population>Full analysis set of all patients in the safety analysis set (those randomized who received at least 1 dose of trial product) with at least 1 measurement of ADA titres at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patients with ADA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patients without ADA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Treatment-induced ADA</title>
        <description>Percentage of the total number of evaluable patients that were ADA negative at baseline and ADA positive after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies</description>
        <time_frame>104 days after the first dose</time_frame>
        <population>Full analysis set of all patients in the safety analysis set (those randomized who received at least 1 dose of trial product) with at least 1 measurement of ADA titres at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Treatment-induced ADA</title>
          <description>Percentage of the total number of evaluable patients that were ADA negative at baseline and ADA positive after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies</description>
          <population>Full analysis set of all patients in the safety analysis set (those randomized who received at least 1 dose of trial product) with at least 1 measurement of ADA titres at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patients with ADA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patients without ADA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Treatment-boosted ADA</title>
        <description>Percentage of baseline ADA-positive patients with significant increases (≥5-fold) in ADA titre after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies</description>
        <time_frame>104 days after the first dose</time_frame>
        <population>Full analysis set of all patients in the safety analysis set (those randomized who received at least 1 dose of trial product) with at least 1 measurement of ADA titres at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Treatment-boosted ADA</title>
          <description>Percentage of baseline ADA-positive patients with significant increases (≥5-fold) in ADA titre after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies</description>
          <population>Full analysis set of all patients in the safety analysis set (those randomized who received at least 1 dose of trial product) with at least 1 measurement of ADA titres at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patients with ADA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patients without ADA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of ADA Response - Neutralizing Activity</title>
        <description>Percentage of ADA positive patients with ADA neutralizing activity. ADA = antidrug antibodies.</description>
        <time_frame>104 days after the first dose</time_frame>
        <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of ADA Response - Neutralizing Activity</title>
          <description>Percentage of ADA positive patients with ADA neutralizing activity. ADA = antidrug antibodies.</description>
          <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of ADA Response - Titer of Neutralizing Activity</title>
        <description>Titre of neutralizing activity of ADA positive patients. ADA = antidrug antibodies.</description>
        <time_frame>104 days after the first dose</time_frame>
        <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response in terms of titre of neutralizing activity.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of ADA Response - Titer of Neutralizing Activity</title>
          <description>Titre of neutralizing activity of ADA positive patients. ADA = antidrug antibodies.</description>
          <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response in terms of titre of neutralizing activity.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of ADA Response - Cross-reactivity</title>
        <description>Percentage of ADA positive patients with cross-reactivity towards endogenous glucagon. ADA = antidrug antibodies.</description>
        <time_frame>104 days after the first dose</time_frame>
        <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response in terms of cross-reactivity towards endogenous glucagon.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of ADA Response - Cross-reactivity</title>
          <description>Percentage of ADA positive patients with cross-reactivity towards endogenous glucagon. ADA = antidrug antibodies.</description>
          <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response in terms of cross-reactivity towards endogenous glucagon.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of ADA Response - Timing</title>
        <description>The timing of detected ADA response. ADA = antidrug antibodies.</description>
        <time_frame>104 days after the first dose</time_frame>
        <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response in terms of timing.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of ADA Response - Timing</title>
          <description>The timing of detected ADA response. ADA = antidrug antibodies.</description>
          <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response in terms of timing.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of ADA Response - Duration</title>
        <description>The Duration of detected ADA response. ADA = antidrug antibodies.</description>
        <time_frame>104 days after the first dose</time_frame>
        <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response in terms of duration.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Characterization of ADA Response - Duration</title>
          <description>The Duration of detected ADA response. ADA = antidrug antibodies.</description>
          <population>No ADAs were recorded in this trial, therefore it was not possible to characterize the ADA response in terms of duration.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Area Under the Plasma Concentration Curve</title>
        <description>Area under the plasma concentration curve (AUC) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.</description>
        <time_frame>0-30 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Area Under the Plasma Concentration Curve</title>
          <description>Area under the plasma concentration curve (AUC) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>h*pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425" spread="220"/>
                    <measurement group_id="O2" value="548" spread="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499" spread="371"/>
                    <measurement group_id="O2" value="546" spread="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Area Under the Plasma Concentration Curve</title>
        <description>Area under the plasma concentration curve (AUC) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
        <time_frame>0-90 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Area Under the Plasma Concentration Curve</title>
          <description>Area under the plasma concentration curve (AUC) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>h*pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1560" spread="615"/>
                    <measurement group_id="O2" value="1290" spread="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1640" spread="611"/>
                    <measurement group_id="O2" value="1290" spread="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Maximum Plasma Concentration</title>
        <description>Maximum plasma concentration (Cmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
        <time_frame>90 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Maximum Plasma Concentration</title>
          <description>Maximum plasma concentration (Cmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1390" spread="609"/>
                    <measurement group_id="O2" value="1490" spread="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1820" spread="2460"/>
                    <measurement group_id="O2" value="1430" spread="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Time to Maximum Plasma Concentration</title>
        <description>Time to maximum plasma concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
        <time_frame>90 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Time to Maximum Plasma Concentration</title>
          <description>Time to maximum plasma concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.167" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.483" lower_limit="0.0833" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.0833" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0833" upper_limit="0.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics - Area Under the Effect Curve</title>
        <description>Plasma glucose profiles, area under the effect curve (AUE) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.</description>
        <time_frame>0-30 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics - Area Under the Effect Curve</title>
          <description>Plasma glucose profiles, area under the effect curve (AUE) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>h*mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.799" spread="0.449"/>
                    <measurement group_id="O2" value="0.886" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.869" spread="0.375"/>
                    <measurement group_id="O2" value="0.895" spread="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics - Area Under the Effect Curve</title>
        <description>Plasma glucose profiles, area under the effect curve (AUE) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
        <time_frame>0-90 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics - Area Under the Effect Curve</title>
          <description>Plasma glucose profiles, area under the effect curve (AUE) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>h*mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.42"/>
                    <measurement group_id="O2" value="5.86" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" spread="2.28"/>
                    <measurement group_id="O2" value="6.04" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics - Change From Baseline Plasma Glucose</title>
        <description>Change from baseline plasma glucose to maximum plasma glucose (CEmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
        <time_frame>90 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics - Change From Baseline Plasma Glucose</title>
          <description>Change from baseline plasma glucose to maximum plasma glucose (CEmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="2.5"/>
                    <measurement group_id="O2" value="6" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" spread="2.43"/>
                    <measurement group_id="O2" value="6.21" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics - Time to Maximum Plasma Glucose Concentration</title>
        <description>Time to maximum plasma glucose concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
        <time_frame>90 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics - Time to Maximum Plasma Glucose Concentration</title>
          <description>Time to maximum plasma glucose concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.0833" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.483" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.167" upper_limit="1.58"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0833" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics - An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment</title>
        <description>An increase in the plasma glucose concentration of ≥20 mg/dL within 30 minutes after treatment at visit 2 and visit 4. Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
        <time_frame>30 minutes</time_frame>
        <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon (ZP4207)</title>
            <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen</title>
            <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics - An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment</title>
          <description>An increase in the plasma glucose concentration of ≥20 mg/dL within 30 minutes after treatment at visit 2 and visit 4. Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.</description>
          <population>PK/PD set: all patients in the safety analysis set (patients who were randomized and received at least 1 dose of trial product) with at least 1 pre- and post-dose PK value at 1 visit. PK = pharmacokinetic. PD = pharmacodynamic.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>104 days</time_frame>
      <desc>Adverse events were recorded at each trial visit by the investigator or other designated trial personnel.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dasiglucagon (ZP4207)</title>
          <description>3 repeated doses (s.c.injection) of 0.6 mg dasiglucagon, with 1 week between each dose.&#xD;
dasiglucagon: Glucagon Analog</description>
        </group>
        <group group_id="E2">
          <title>GlucaGen</title>
          <description>3 repeated doses (s.c.injection) of 1.0 mg GlucaGen, with 1 week between each dose.&#xD;
GlucaGen: Native Glucagon</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="43" subjects_affected="26" subjects_at_risk="57"/>
                <counts group_id="E2" events="33" subjects_affected="23" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="580" subjects_affected="27" subjects_at_risk="57"/>
                <counts group_id="E2" events="447" subjects_affected="29" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kim Mark Knudsen</name_or_title>
      <organization>Zealand Pharma A/S</organization>
      <phone>+45 50603780</phone>
      <email>KMKnudsen@zealandpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

